{"id":474522,"date":"2021-04-10T08:33:41","date_gmt":"2021-04-10T12:33:41","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=474522"},"modified":"2021-04-10T08:33:41","modified_gmt":"2021-04-10T12:33:41","slug":"cardiff-oncology-in-collaboration-with-mit-presents-gene-signature-analyses-data-identifying-androgen-independent-mechanism-for-onvansertib-abiraterone-synergy-in-mcrpc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-in-collaboration-with-mit-presents-gene-signature-analyses-data-identifying-androgen-independent-mechanism-for-onvansertib-abiraterone-synergy-in-mcrpc\/","title":{"rendered":"Cardiff Oncology in Collaboration with MIT Presents Gene Signature Analyses Data Identifying Androgen-Independent Mechanism for Onvansertib-Abiraterone Synergy in mCRPC"},"content":{"rendered":"
\n

– Onvansertib and the androgen receptor (AR) signaling inhibitor abiraterone synergize in an AR-independent manner in in-vitro and in-vivo metastatic castrate-resistant prostate cancer (mCRPC) models<\/h2>\n

– AR-independent effects of abiraterone include the upregulation of a mitosis-related gene signature and disruption of mitotic spindle orientation, rendering cancer cells more susceptible to onvansertib induced cell death<\/h2>\n

– Ongoing analyses of archived tissue from patients enrolled in the ongoing Phase 2 mCRPC trial aims to determine if the identified gene signature is predictive of patient response to onvansertib-abiraterone combination therapy<\/h2>\n

– The identified gene signature could support a precision medicine approach to treatment by enabling the identification of patients most likely to benefit from the combination<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n SAN DIEGO<\/span>, April 10, 2021<\/span> \/PRNewswire\/ — Cardiff Oncology, Inc. <\/b>(Nasdaq:\u00a0CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer and castrate-resistant prostate cancer, in collaboration with scientists in the Center for Precision Cancer Medicine at the Massachusetts Institute of Technology<\/span> (MIT<\/span>), today announced that new gene signature and mechanistic analyses related to its ongoing Phase 2 trial of onvansertib in metastatic castrate-resistant prostate cancer (mCRPC) were featured in a virtual oral poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021.<\/p>\n

\n

\n
\n \"Cardiff
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Analyses presented in the poster suggest that the androgen receptor signaling inhibitor (ARSi) abiraterone sensitizes certain prostate cancer cells to onvansertib by upregulating a set of mitosis related genes and disrupting mitotic spindle orientation. These results are consistent with previous findings showing that onvansertib and abiraterone synergize in an androgen receptor (AR)-independent manner in-vitro and in-vivo.<\/p>\n

“The latest results from our collaborative studies with Cardiff Oncology provide important insight into the mechanisms of synergy between onvansertib and abiraterone in mCRPC,” said Michael B. Yaffe<\/span>, M.D., Ph.D., David H. Koch Professor of Science and Professor of Biology and Biological Engineering at the Massachusetts Institute of Technology<\/span>. “Data showing a cellular mechanism for how these two compounds synergize in an AR-independent manner provide a strong scientific rationale for Cardiff Oncology’s ongoing Phase 2 trial and explain how the addition of onvansertib can improve clinical outcomes in patients showing initial abiraterone resistance. We have also identified a set of genes that appear to drive this mechanism of onvansertib-abiraterone synergy as well as predict patient response and archived clinical trial tissue from patients enrolled in the ongoing trial are being analyzed to confirm this hypothesis.”<\/p>\n

\n Mark Erlander<\/span>, Ph.D., chief executive officer of Cardiff Oncology added, “The identification of a gene signature that appears to predict patient response to onvansertib-abiraterone combination therapy is encouraging, as is the finding that this signature is enriched in mCRPC patients with the known molecular basal tumor subtype. We look forward to continuing to work with our collaborators at MIT<\/span> and Decipher Biosciences to validate this gene set as a predictive response biomarker. Validation of such a biomarker would be significant, as it would allow us to take a precision medicine approach to future trials by enabling the identification of patients most likely to benefit from therapy with onvansertib.” <\/p>\n

\n Highlights from the AACR presentation include:<\/b>\n <\/p>\n